Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.40 |
| ▸ | TSHR | P16473 | 6/20 | 0.40 |
| ▸ | PPARG | P37231 | 6/20 | 0.40 |
| ▸ | PPARD | Q03181 | 6/20 | 0.40 |
| ▸ | PPARA | Q07869 | 6/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28058520 | 1.00 | NAAA (0.44) | NAAACES2HCAR2EPHX1GPR84 | |
| SCHEMBL28058492 | 1.00 | NAAA (0.44) | NAAACES2HCAR2EPHX1GPR84 | |
| SCHEMBL28058421 | 1.00 | NAAA (0.44) | NAAACES2HCAR2EPHX1GPR84 | |
| SCHEMBL28058525 | 1.00 | NAAA (0.44) | NAAACES2HCAR2EPHX1GPR84 | |
| SCHEMBL5672266 | 1.00 | NAAA (0.44) | NAAACES2HCAR2EPHX1GPR84 | |
| SCHEMBL28058414 | 1.00 | NAAA (0.44) | NAAACES2HCAR2EPHX1GPR84 | |
| SCHEMBL28058521 | 1.00 | NAAA (0.44) | NAAACES2HCAR2EPHX1GPR84 | |
| SCHEMBL29172804 | 1.00 | NAAA (0.44) | NAAACES2HCAR2EPHX1GPR84 | |
| SCHEMBL7519579 | 0.98 | NAAA (0.42) | NAAACES2HCAR2EPHX1GPR84 | |
| SCHEMBL3011295 | 0.98 | NAAA (0.42) | NAAACES2HCAR2EPHX1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303258-B1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2006-10-11 | — | — | EP | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2024-01-11 | — | — | US | disclosed |
| WO-2023032996-A1 | COMPOUND AND LABELED BIOMATERIAL USING SAME | 富士フイルム株式会社 | 2023-03-09 | — | — | WO | disclosed |
| CN-108064232-B | Peptides | 豪夫迈·罗氏有限公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-107001423-B | Peptides | 豪夫迈·罗氏有限公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-3308164-A1 | HIGH THROUGHPUT OPTIMIZATION OF CONTENT-LOADED NANOPARTICLES | Danmarks Tekniske Universitet (DK) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198609-A1 | HIGH THROUGHPUT OPTIMIZATION OF CONTENT-LOADED NANOPARTICLES | DANMARKS TEKNISKE UNIVERSITET (DK) | 2016-12-15 | — | — | WO | disclosed |
| CN-105579431-A | Ether-containing monoester compound and use thereof | MORESCO CORP | 2016-05-11 | — | — | CN | disclosed |
| CN-104010626-A | Prevention and treatment of ocular conditions | ASCENDIS PHARMA AS | 2014-08-27 | — | — | CN | disclosed |
| EP-1303258-B1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2006-10-11 | — | — | EP | disclosed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | disclosed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SPINT2, SERPINB1 | NAAA 2250/4885CES2 2667/4885HCAR2 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.